The sustained tumor control in the HER2/neu group aligns with our in vitro findings, where anti-HER2/neu TCR T cells exhibited enhanced secretion of effector molecules, as well as increased cytotoxicity against antigen-expressing target cells (See Figures 1, 3). Here, ERBB2 is linked to neoplasm.